The FDA issued a warning letter to McKesson for violations concerning a possible distribution of illegitimate opioid products while calling for action in securing the supply chain from illegitimate medications, especially opioids.
‘The orchestrators of the immune system’: Partnership develops antibody therapies
from BioPharma-Reporter.com
FDA observes manipulation of data at Immunomedics facility
from BioPharma-Reporter.com
EMA implored to improve trial reporting, with over 50% of trials still missing results
from Outsourcing-Pharma.com
Tech is advancing, but uncertainty creates an ‘opposing effect’ to positive movement
from Outsourcing-Pharma.com
European manufacturing waiver to ‘level the playing field’
Globalisation
FDA seeks transparent relationship on manufacturing standards
Lifecycle Management
With medicine tracking operational, what does this mean for industry?
Globalisation
FDA secures supply chain with pilot program testing tech
Counterfeiting
